logo
AI Icon𝛼SK or Search
ENTITY

Duality Biotherapeutics (9606 HK)

71
Analysis
Health Care • China
Duality Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation antibody-drug conjugates (ADCs) to treat cancer and autoimmune diseases. The company develops a pipeline of ADC candidates, including DB-1303/BNT323 (HER2 ADC), DB-1311/BNT324 (B7-H3 ADC), DB-1310 (HER3 ADC), and DB-1305/BNT325 (TROP2 ADC), for various cancers. Duality Biotherapeutics is headquartered in Shanghai, China, and was founded in 2019.
more
Exchange Announcement • 14 Oct 2026 18:53

Next Day Disclosure Return

Exchange Announcement • 29 Sep 2026 21:20

Next Day Disclosure Return

Exchange Announcement • 28 Sep 2026 20:57

Next Day Disclosure Return

Exchange Announcement • 28 Sep 2026 19:52

2026 Interim Report

Exchange Announcement • 28 Aug 2026 18:32

Interim Results Announcement For The Six Months Ended June 30, 2026

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x